Enhanced Crenolanib Therapy for FLT3 Mutated Proliferative Disorders

This inventive concept discloses novel approaches to improve the efficacy and safety of crenolanib treatment for FLT3 mutated proliferative disorders, addressing the limitations of prior art.

The original patent (Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment) disclosed the use of crenolanib for treating FLT3 mutated proliferative disorders. However, the existing treatment methods have limitations, such as adverse effects, variable efficacy, and limited patient selection criteria. The new inventive concept addresses these limitations by providing direct improvements and enhancements to the original treatment methods.

The new inventive concept encompasses four main aspects: 1) a system for treating FLT3 mutated proliferative disorders with a reduced risk of adverse effects, achieved through a novel crenolanib dosing regimen and companion diagnostic; 2) a method for enhancing the efficacy of crenolanib by co-administering a FLT3-activating agent to increase FLT3 tyrosine kinase activity; 3) a pharmaceutical composition comprising crenolanib and a FLT3-targeting RNAi molecule, which reduces FLT3 expression and enhances the anti-cancer activity of crenolanib; and 4) a method for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment, combining crenolanib with a HDAC inhibitor to enhance the anti-cancer activity of crenolanib. Additionally, a kit for treating FLT3 mutated proliferative disorders is disclosed, comprising a crenolanib dosage form, a companion diagnostic, and instructions for use.

The new inventive concept introduces novel and non-obvious improvements to the original patent, including the use of a FLT3-activating agent, FLT3-targeting RNAi molecule, and HDAC inhibitor, which were not disclosed or suggested in the prior art. The inventive concept's novelty lies in the combination of these elements, which provide a synergistic effect in enhancing the efficacy and safety of crenolanib treatment.

Alternative embodiments of the inventive concept include using different FLT3-activating agents, RNAi molecules, or HDAC inhibitors. Variations of the pharmaceutical composition could comprise different ratios of crenolanib to FLT3-targeting RNAi molecule or different formulations of the composition. The kit for treating FLT3 mutated proliferative disorders could be modified to include additional components, such as patient education materials or monitoring tools.

The enhanced crenolanib therapy disclosed in this inventive concept has significant commercial potential in the oncology market, particularly in the treatment of FLT3 mutated proliferative disorders. The improved efficacy and safety of the treatment method could lead to increased adoption and market share, resulting in substantial revenue growth for pharmaceutical companies and improved patient outcomes.